3.48
+0.058(+1.70%)
Currency In EUR
Address
Friedrich-Miescher-Strasse 15
Tübingen, 72076
Germany
Phone
49 7071 9883 0
Website
Sector
Healthcare
Industry
Biotechnology
Employees
825
First IPO Date
August 14, 2020
| Name | Title | Pay | Year Born |
| Alexander Zehnder | Chief Executive Officer, MD & Member of Management Board | 929,699 | 1970 |
| Ulrike Gnad-Vogt | Senior Vice President & Area Head of Oncology | 284,145 | 1973 |
| Axel-Sven Malkomes | Chief Financial Officer & Member of Executive Board | 486,661 | 1967 |
| Malte Greune | COO, Member of Management Board & MD | 540,751 | 1965 |
| Thaminda Ramanayake | Chief Business Officer & Member of Executive Board | 586,630 | 1977 |
| Myriam Mendila | Chief Scientific Officer, Head of R&D, MD & Member of the Management Board | 605,480 | 1966 |
| Patrick Baumhof | Senior Vice President of Technology | 0 | N/A |
| Sarah Fakih | Vice President of Corporate Communications & Investor Relations | 0 | N/A |
| Marco Rau | General Counsel | 0 | N/A |
| Slavica Stevanovic-Heck | Head of Human Resources | 0 | N/A |
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratiory syncytial virus, rotavirus, malaria, and universal influenza. The company also develops RNA-based cancer immunotherapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck. The company was founded in 2000 and is headquartered in Tübingen, Germany.